Global Erythropoietin Stimulating Agents Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Erythropoietin Stimulating Agents Market Insights, Forecast to 2034
Erythropoiesis-stimulating agents (ESA) are medications which stimulate the bone marrow to make red blood cells. They are used to treat anemia due to end stage kidney disease, chemotherapy, major surgery, or certain treatments in HIV/AIDS.
Market Analysis and InsightsGlobal Erythropoietin Stimulating Agents Market
Global Erythropoietin Stimulating Agents market is expected to reach to US$ 9779 million in 2023, with a positive growth of %, compared with US$ 8939 million in 2022. Backed with the increasing demand from downstream industries, Erythropoietin Stimulating Agents industry is evaluated to reach US$ 12520 million in 2033. The CAGR will be 4.2% during 2023 to 2033.
Globally, Erythropoietin Stimulating Agents key companies include Pfizer, Amgen, BioSidus, Biocon, Celltrion, Roche, Intas Pharmaceuticals, Johnson & Johnson and Teva Pharmaceutical Industries, etc. Pfizer, Amgen, BioSidus are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of Erythropoietin Stimulating Agents were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033 and the share will be % in 2033. Moreover, China, plays a key role in the whole Erythropoietin Stimulating Agents market and estimated to attract more attentions from industry insiders and investors.
Erythropoietin Stimulating Agents can be divided into Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa and Others, etc. Epoetin Alfa is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2033.
Erythropoietin Stimulating Agents is widely used in various fields, such as Hospitals, Clinics and Others,, etc. Hospitals provides greatest supports to the Erythropoietin Stimulating Agents industry development. In 2022, global % revenue of Erythropoietin Stimulating Agents went into Hospitals filed and the proportion will reach to % in 2033.
Report Covers
This report presents an overview of global Erythropoietin Stimulating Agents market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Erythropoietin Stimulating Agents market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
Pfizer
Amgen
BioSidus
Biocon
Celltrion
Roche
Intas Pharmaceuticals
Johnson & Johnson
Teva Pharmaceutical Industries
Thermo Fisher Scientific
Segment by Type
Epoetin Alfa
Epoetin Beta
Darbepoetin Alfa
Others
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Erythropoietin Stimulating Agents introduction, etc. Erythropoietin Stimulating Agents Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Erythropoietin Stimulating Agents
Chapter 13Methodology and Data Sources adopted by MRAResearch
Market Analysis and InsightsGlobal Erythropoietin Stimulating Agents Market
Global Erythropoietin Stimulating Agents market is expected to reach to US$ 9779 million in 2023, with a positive growth of %, compared with US$ 8939 million in 2022. Backed with the increasing demand from downstream industries, Erythropoietin Stimulating Agents industry is evaluated to reach US$ 12520 million in 2033. The CAGR will be 4.2% during 2023 to 2033.
Globally, Erythropoietin Stimulating Agents key companies include Pfizer, Amgen, BioSidus, Biocon, Celltrion, Roche, Intas Pharmaceuticals, Johnson & Johnson and Teva Pharmaceutical Industries, etc. Pfizer, Amgen, BioSidus are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of Erythropoietin Stimulating Agents were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033 and the share will be % in 2033. Moreover, China, plays a key role in the whole Erythropoietin Stimulating Agents market and estimated to attract more attentions from industry insiders and investors.
Erythropoietin Stimulating Agents can be divided into Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa and Others, etc. Epoetin Alfa is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2033.
Erythropoietin Stimulating Agents is widely used in various fields, such as Hospitals, Clinics and Others,, etc. Hospitals provides greatest supports to the Erythropoietin Stimulating Agents industry development. In 2022, global % revenue of Erythropoietin Stimulating Agents went into Hospitals filed and the proportion will reach to % in 2033.
Report Covers
This report presents an overview of global Erythropoietin Stimulating Agents market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Erythropoietin Stimulating Agents market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
By Company
Pfizer
Amgen
BioSidus
Biocon
Celltrion
Roche
Intas Pharmaceuticals
Johnson & Johnson
Teva Pharmaceutical Industries
Thermo Fisher Scientific
Segment by Type
Epoetin Alfa
Epoetin Beta
Darbepoetin Alfa
Others
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Erythropoietin Stimulating Agents introduction, etc. Erythropoietin Stimulating Agents Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Erythropoietin Stimulating Agents
Chapter 13Methodology and Data Sources adopted by MRAResearch